Search research articles
Contact Us
Filters
Showing results (91-100 of 206) with videos related to
Page
of 21
Sort By:
Scientific Reports
|
January 24, 2020
Nearest Neighbour Propensity Score Matching and Bootstrapping for Estimating Binary Patient Response in Oncology: A Monte Carlo Simulation
Tine Geldof, Dusan Popovic, Nancy Van Damme, et al.
Frontiers in Pharmacology
|
June 17, 2017
Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
Tim A Kanters, Jelena Stevanovic, Isabelle Huys, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
February 26, 2024
Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain
Teresa Barcina Lacosta, Arnold G Vulto, Florian Turk, et al.
Pharmaceuticals (Basel, Switzerland)
|
February 9, 2021
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Pharmaceuticals (Basel, Switzerland)
|
June 2, 2021
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices
Liese Barbier, Steven Simoens, Caroline Soontjens, et al.
Diabetes, Obesity & Metabolism
|
September 1, 2025
Barriers to adoption of biosimilar insulins in Europe: A mixed-methods study
Elif Car, Garm Habets, Arnold G Vulto, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
August 24, 2022
How to select a best-value biological medicine? A practical model to support hospital pharmacists
Liese Barbier, Yannick Vandenplas, Niels Boone, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting
Evelien Moorkens, Steven Simoens, Per Troein, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting
Evelien Moorkens, Steven Simoens, Per Troein, et al.
Frontiers in Medicine
|
March 26, 2021
Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
Eline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.
Page
of 21
Search research articles
Search
Showing results (91-100 of 206) with videos related to
Sort By:
Page
of 21
Scientific Reports
|
January 24, 2020
Nearest Neighbour Propensity Score Matching and Bootstrapping for Estimating Binary Patient Response in Oncology: A Monte Carlo Simulation
Tine Geldof, Dusan Popovic, Nancy Van Damme, et al.
Frontiers in Pharmacology
|
June 17, 2017
Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
Tim A Kanters, Jelena Stevanovic, Isabelle Huys, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
February 26, 2024
Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain
Teresa Barcina Lacosta, Arnold G Vulto, Florian Turk, et al.
Pharmaceuticals (Basel, Switzerland)
|
February 9, 2021
Informing Patients about Biosimilar Medicines: The Role of European Patient Associations
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, et al.
Pharmaceuticals (Basel, Switzerland)
|
June 2, 2021
Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices
Liese Barbier, Steven Simoens, Caroline Soontjens, et al.
Diabetes, Obesity & Metabolism
|
September 1, 2025
Barriers to adoption of biosimilar insulins in Europe: A mixed-methods study
Elif Car, Garm Habets, Arnold G Vulto, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
August 24, 2022
How to select a best-value biological medicine? A practical model to support hospital pharmacists
Liese Barbier, Yannick Vandenplas, Niels Boone, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting
Evelien Moorkens, Steven Simoens, Per Troein, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
April 5, 2019
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting
Evelien Moorkens, Steven Simoens, Per Troein, et al.
Frontiers in Medicine
|
March 26, 2021
Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia
Eline van Overbeeke, Brett Hauber, Sissel Michelsen, et al.
Page
of 21